Bausch Health Companies Inc. agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800 percent price hike in 2015.
Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.
The FDA found high levels of the same type of carcinogen that led to the recall of some hypertension and heartburn medications in some of the extended-release version metformin drugs that had been tested.
Novo Nordisk’s diabetes drug Victoza (liraglutide) earned approval from the U.S. FDA for an expanded indication for use in children ages 10 to 17 years who have type 2 diabetes.
